Immutep (IMMP) Income towards Parent Company (2011 - 2025)
Immutep's (IMMP) quarterly Income towards Parent Company came in at $64.9 million in Q4 2025, down 42.43% YoY from $112.8 million in Q4 2024, and down 29.41% on a QoQ basis from $92.0 million in Q2 2025.
Immutep (IMMP) Income towards Parent Company (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 13 years of Income towards Parent Company data on file, last reported at $64.9 million in Q4 2025.
- Quarterly Income towards Parent Company fell 42.43% year-over-year to $64.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $64.9 million (down 42.43% YoY) and the FY2025 annual result came in at $92.0 million, down 26.35% from the prior year.
- Income towards Parent Company declined to $64.9 million in Q4 2025, from $92.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $124.9 million in Q2 2024 to a low of $50.4 million in Q4 2022.
- A 5-year average of $81.5 million and a median of $77.3 million in 2021 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2021 — Income towards Parent Company jumped 158.52% — and 2025, when it tumbled 42.43%.
- Tracing IMMP's Income towards Parent Company over 5 years: stood at $79.3 million in 2021, then tumbled by 36.48% to $50.4 million in 2022, then jumped by 49.41% to $75.3 million in 2023, then surged by 49.82% to $112.8 million in 2024, then plunged by 42.43% to $64.9 million in 2025.
- The last three Income towards Parent Company figures came in at $64.9 million (Q4 2025), $92.0 million (Q2 2025), and $112.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.93 Mn |
| Jun 30, 2025 | 91.99 Mn |
| Dec 31, 2024 | 112.79 Mn |
| Jun 30, 2024 | 124.90 Mn |
| Dec 31, 2023 | 75.28 Mn |
| Jun 30, 2023 | 91.21 Mn |
| Dec 31, 2022 | 50.39 Mn |
| Jun 30, 2022 | 67.38 Mn |
| Dec 31, 2021 | 79.32 Mn |
| Jun 30, 2021 | 56.42 Mn |
| Dec 31, 2020 | 44.36 Mn |
| Jun 30, 2020 | 21.83 Mn |
| Dec 31, 2019 | 19.15 Mn |
| Jun 30, 2019 | 17.08 Mn |
| Dec 31, 2018 | 24.05 Mn |
| Jun 30, 2018 | 25.38 Mn |
| Jun 30, 2017 | -2.31 Mn |
| Mar 31, 2017 | -1.69 Mn |
| Dec 31, 2016 | -47,793.34 |
| Jun 30, 2016 | -2.63 Mn |